Dominant contribution of P450 3A4 to the hepatic carcinogenic activation of aflatoxin B1

Chemical Research in Toxicology

Volumn 19, Issue 4, 2006, Pages 577-586

  Kamdem, Landry K ^a   Meineke, Ingolf ^a   Gödtel Armbrust, Ute ^b   Brockmöller, Jürgen ^a   Wojnowski, Leszek ^b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN B1; AFLATOXIN B1 8,9 EPOXIDE; CARCINOGEN; CYTOCHROME P450 1A2; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 3A7; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENICITY; DETOXIFICATION; ENZYME KINETICS; ENZYME SPECIFICITY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER METABOLISM; LIVER MICROSOME METABOLISM; MALE; METABOLITE; MODEL; PROTEIN EXPRESSION; TOXICOKINETICS;

AFLATOXIN B1; BIOTRANSFORMATION; CARCINOGENS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; LIVER;

EID: 33646084391     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx050358e     Document Type: Article

References (50)

1. Hall, A. J., and Wild, C. P. (2003) Liver cancer in low and middle income countries. BMJ 326, 994-995.
2. Wild, C. P., and Hall, A. J. (2000) Primary prevention of hepatocellular carcinoma in developing countries. Mutat. Res. 462, 381-393.
3. Wild, C. P., and Turner, P. C. (2002) The toxicology of aflatoxins as a basis for public health decisions. Mutagenesis 17, 471-481.
4. Ramsdell, H. S., Parkinson, A., Eddy, A. C., and Eaton, D. L. (1991) Bioactivation of aflatoxin B1 by human liver microsomes: Role of cytochrome P450 IIIA enzymes. Toxicol. Appl. Pharmacol. 108, 436-447.
5. Gallagher, E. P., Kunze, K. L., Stapleton, P. L., and Eaton, D. L. (1996) The kinetics of aflatoxin B1 oxidation by human cDNA-expressed and human liver microsomal cytochromes P450 1A2 and 3A4. Toxicol. Appl. Pharmacol. 141, 595-606.
6. Gallagher, E. P., Wienkers, L. C., Stapleton, P. L., Kunze, K. L., and Eaton, D. L. (1994) Role of human microsomal and human complementary DNA-expressed cytochromes P4501A2 and P4503A4 in the bioactivation of aflatoxin B1. Cancer. Res. 54, 101-108.
7. Aoyama, T., Yamano, S., Guzelian, P. S., Gelboin, H. V., and Gonzalez, F. J. (1990) Five of 12 forms of vaccinia virus-expressed human hepatic cytochrome P450 metabolically activate aflatoxin B1. Proc. Natl. Acad. Sci. U.S.A. 87, 4790-4793.
8. Ueng, Y. F., Shimada, T., Yamazaki, H., and Guengerich, F. P. (1995) Oxidation of aflatoxin B1 by bacterial recombinant human cytochrome P450 enzymes. Chem. Res. Toxicol. 8, 218-225.
9. Forrester, L. M., Neal, G. E., Judah, D. J., Glancey, M. J., and Wolf, C. R. (1990) Evidence for involvement of multiple forms of cytochrome P-450 in aflatoxin B1 metabolism in human liver. Proc. Natl. Acad. Sci. U.S.A. 87, 8306-8310.
10. Van Vleet, T. R., Klein, P. J., and Coulombe, R. A., Jr. (2002) Metabolism and cytotoxicity of aflatoxin b1 in cytochrome p-450-expressing human lung cells. J. Toxicol. Environ. Health A 65, 853-867.
11. Doi, A. M., Patterson, P. E., and Gallagher, E. P. (2002) Variability in aflatoxin B(1)-macromolecular binding and relationship to biotransformation enzyme expression in human prenatal and adult liver. Toxicol. Appl. Pharmacol. 181, 48-59.
12. Wang, H., Dick, R., Yin, H., Licad-Coles, E., Kroetz, D. L., Szklarz, G., Harlow, G., Halpert, J. R., and Correia, M. A. (1998) Structure-function relationships of human liver cytochromes P450 3A: Aflatoxin B1 metabolism as a probe. Biochemistry 37, 12536-12545.
13. Xue, L., Wang, H. F., Wang, Q., Szklarz, G. D., Domanski, T. L., Halpert, J. R., and Correia, M. A. (2001) Influence of P450 3A4 SRS-2 residues on cooperativity and/or regioselectivity of aflatoxin B(1) oxidation. Chem. Res. Toxicol. 14, 483-491.
14. Wrighton, S. A., Brian, W. R., Sari, M. A., Iwasaki, M., Guengerich, F. P., Raucy, J. L., Molowa, D. T., and Vandenbranden, M. (1990) Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol. Pharmacol. 38, 207-213.
15. Wrighton, S. A., Ring, B. J., Watkins, P. B., and VandenBranden, M. (1989) Identification of a polymorphically expressed member of the human cytochrome P-450III family. Mol. Pharmacol. 36, 97-105.
16. Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J., Watkins, P. B., Daly, A., Wrighton, S. A., Hall, S. D., Maurel, P., Relling, M., Brimer, C., Yasuda, K., Venkataramanan, R., Strom, S., Thummel, K., Boguski, M. S., and Schuetz, E. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27, 383-391.
17. Hustert, E., Haberl, M., Burk, O., Wolbold, R., He, Y. Q., Klein, K., Nuessler, A. C., Neuhaus, P., Klattig, J., Eiselt, R., Koch, I., Zibat, A., Brockmoller, J., Halpert, J. R., Zanger, U. M., and Wojnowski, L. (2001) The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11, 773-779.
18. Wojnowski, L., Turner, P. C., Pedersen, B., Hustert, E., Brockmoller, J., Mendy, M., Whittle, H. C., Kirk, G., and Wild, C. P. (2004) Increased levels of aflatoxin-albumin adducts are associated with CYP3A5 polymorphisms in The Gambia, West Africa. Pharmacogenetics 14, 691-700.
19. Tateishi, T., Watanabe, M., Moriya, H., Yamaguchi, S., Sato, T., and Kobayashi, S. (1999) No ethnic difference between Caucasian and Japanese hepatic samples in the expression frequency of CYP3A5 and CYP3A7 proteins. Biochem. Pharmacol. 57, 935-939.
20. Gillam, E. M., Guo, Z., Ueng, Y. F., Yamazaki, H., Cock, I., Reilly, P. E., Hooper, W. D., and Guengerich, F. P. (1995) Expression of cytochrome P450 3A5 in Escherichia coli: Effects of 5′ modification, purification, spectral characterization, reconstitution conditions, and catalytic activities. Arch. Biochem. Biophys. 317, 374-384
21. [Gillam, E. M., Guo, Z., Ueng, Y. F., Yamazaki, H., Cock, I., Reilly, P. E., Hooper, W. D., and Guengerich, F. P. (1995) Published erratum. Arch. Biochem. Biophys. 318 (2), 498].
22. Ueng, Y. F., Kuwabara, T., Chun, Y. J., and Guengerich, F. P. (1997) Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 36, 370-381.
23. Sim, S. C., Edwards, R. J., Boobis, A. R., and Ingelman-Sundberg, M. (2005) CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele. Pharmacogenet. Genomics 15, 625-631.
24. Schweikl, H., Taylor, J. A., Kitareewan, S., Linko, P., Nagorney, D., and Goldstein, J. A. (1993) Expression of CYP1A1 and CYP1A2 genes in human liver. Pharmacogenetics 3, 239-249.
25. Lamba, J. K., Lin, Y. S., Schuetz, E. G., and Thummel, K. E. (2002) Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Delivery Rev. 54, 1271-1294.
26. Evert, B., Eichelbaum, M., Haubruck, H., and Zanger, U. M. (1997) Functional properties of CYP2D6 1 (wild-type) and CYP2D6 7 (His324Pro) expressed by recombinant baculovirus in insect cells. Naunyn-Schmiedebergs Arch. Pharmacol. 355, 309-318.
27. Venkatakrishnan, K., von Moltke, L. L., Court, M. H., Harmatz, J. S., Crespi, C. L., and Greenblatt, D. J. (2000) Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: Ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab. Dispos. 28, 1493-1504.
28. Yuan, R., Madani, S., Wei, X. X., Reynolds, K., and Huang, S. M. (2002) Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab. Dispos. 30, 1311-1319.
29. Groopman, J. D., Hall, A. J., Whittle, H., Hudson, G. J., Wogan, G. N., Montesano, R., and Wild, C. P. (1992) Molecular dosimetry of aflatoxin-N7-guanine in human urine obtained in The Gambia, West Africa. Cancer Epidemiol. Biomarkers Prev. 1, 221-227.
30. Floyd, M. D., Gervasini, G., Masica, A. L., Mayo, G., George, A. L., Jr., Bhat, K., Kim, R. B., and Wilkinson, G. R. (2003) Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics 13, 595-606.
31. Kamdem, L. K., Streit, F., Zanger, U. M., Brockmoller, J., Oellerich, M., Armstrong, V. W., and Wojnowski, L. (2005) Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin. Chem. 51, 1374-1381.
32. Huang, W., Lin, Y. S., McConn, D. J., 2nd, Calamia, J. C., Totah, R. A., Isoherranen, N., Glodowski, M., and Thummel, K. E. (2004) Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab. Dispos. 32, 1434-1445.
33. Kamdem, L. K., Meineke, I., Koch, I., Zanger, U. M., Brockmoller, J., and Wojnowski, L. (2004) Limited contribution of CYP3A5 to the hepatic 6beta-hydroxylation of testosterone. Naunyn-Schmiedebergs Arch. Pharmacol. 370, 71-77.
34. Neal, G. E., Eaton, D. L., Judah, D. J., and Verma, A. (1998) Metabolism and toxicity of aflatoxins M1 and B1 in human-derived in vitro systems. Toxicol. Appl. Pharmacol. 151, 152-158.
35. Bujons, J., Hsieh, D. P., Kado, N. Y., and Messeguer, A. (1995) Aflatoxin M1 8,9-epoxide: Preparation and mutagenic activity. Chem. Res. Toxicol. 8, 328-332.
36. Loveland, P. M., Wilcox, J. S., Hendricks, J. D., and Bailey, G. S. (1988) Comparative metabolism and DNA binding of aflatoxin B1, aflatoxin M1, aflatoxicol and aflatoxicol-M1 in hepatocytes from rainbow trout (Salmo gairdneri). Carcinogenesis 9, 441-446.
37. Ramsdell, H. S., and Eaton, D. L. (1990) Species susceptibility to aflatoxin B1 carcinogenesis: Comparative kinetics of microsomal biotransformation. Cancer Res. 50, 615-620.
38. Mykkanen, H., Zhu, H., Salminen, E., Juvonen, R. O., Ling, W., Ma, J., Polychronaki, N., Kemilainen, H., Mykkanen, O., Salminen, S., and El-Nezami, H. (2005) Fecal and urinary excretion of aflatoxin B1 metabolites (AFQ1, AFM1 and AFB-N7-guanine) in young Chinese males. Int. J. Cancer 115, 879-884.
39. Groopman, J. D., Wang, J. S., and Scholl, P. (1996) Molecular biomarkers for aflatoxins: From adducts to gene mutations to human liver cancer. Can. J. Physiol. Pharmacol 74, 203-209.
40. Groopman, J. D., Wild, C. P., Hasler, J., Junshi, C., Wogan, G. N., and Kensler, T. W. (1993) Molecular epidemiology of aflatoxin exposures: Validation of aflatoxin-N7-guanine levels in urine as a biomarker in experimental rat models and humans. Environ. Health Perspect. 99, 107-113.
41. Qian, G. S., Ross, R. K., Yu, M. C., Yuan, J. M., Gao, Y. T., Henderson, B. E., Wogan, G. N., and Groopman, J. D. (1994) A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol. Biomarkers Prev. 3, 3-10.
42. Guengerich, F. P., and Kim, D. H. (1990) In vitro inhibition of dihydropyridine oxidation and aflatoxin B1 activation in human liver microsomes by naringenin and other flavonoids. Carcinogenesis 11, 2275-2279.
43. Raney, K. D., Coles, B., Guengerich, F. P., and Harris, T. M. (1992) The endo-8,9-epoxide of aflatoxin B1: A new metabolite. Chem. Res. Toxicol. 5, 333-335.
44. Raney, K. D., Meyer, D. J., Ketterer, B., Harris, T. M., and Guengerich, F. P. (1992) Glutathione conjugation of aflatoxin B1 exo- and endoepoxides by rat and human glutathione S-transferases. Chem. Res. Toxicol. 5, 470-478.
45. Raney, K. D., Shimada, T., Kim, D. H., Groopman, J. D., Harris, T. M., and Guengerich, F. P. (1992) Oxidation of aflatoxins and sterigmatocystin by human liver microsomes: significance of aflatoxin Q1 as a detoxication product of aflatoxin B1. Chem. Res. Toxicol. 5, 202-210.
46. Shimada, T., and Guengerich, F. P. (1989) Evidence for cytochrome P-450NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver. Proc. Natl. Acad. Sci. U.S.A. 86, 462-465.
47. Kensler, T. W., Qian, G. S., Chen, J. G., and Groopman, J. D. (2003) Translational strategies for cancer prevention in liver. Nat. Rev. Cancer 3, 321-329.
48. Lucey, M. R., Kolars, J. C., Merion, R. M., Campbell, D. A., Aldrich, M., and Watkins, P. B. (1990) Cyclosporin toxicity at therapeutic blood levels and cytochrome P-450 IIIA. Lancet 335, 11-15.
49. Burk, O., Koch, I., Raucy, J., Hustert, E., Eichelbaum, M., Brockmoller, J., Zanger, U. M., and Wojnowski, L. (2004) The induction of CYP3A5 in human liver and intestine is mediated by the xenobiotic sensors PXR and CAR. J. Biol. Chem. 279, 38379-38385.
50. Burk, O., Tegude, H., Koch, I., Hustert, E., Wolbold, R., Glaeser, H., Klein, K., Fromm, M. F., Nuessler, A. K., Neuhaus, P., Zanger, U. M., Eichelbaum, M., and Wojnowski, L. (2002) Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine. J. Biol. Chem. 277, 24280-24288.